NASDAQ$CVRX
CVRx Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
CVRx's third quarter performance in 2024 showed strong revenue growth driven by increased adoption of Barostim therapy and favorable reimbursement news.
CVRx reported a 27% increase in revenue for Q3 2024, driven by growth in the U.S. heart failure business. The company saw increases in active implanting centers and sales territories. Gross profit also increased, while R&D expenses decreased. The company expects revenue between $14.5 million and $15.5 million for the fourth quarter of 2024.
- Revenue increased by 27% to $13.4 million compared to Q3 2023.
- U.S. revenue increased by 28% to $12.3 million, driven by growth in the heart failure business.
- Gross profit increased by 26% to $11.1 million, with a gross margin of 83%.
- The company expects revenue between $14.5 million and $15.5 million for the fourth quarter of 2024.
Headline financials
Revenue & EPS history
CVRx · Revenue · Quarterly
$13.4M
Forward guidance
The Company expects to report total revenue between $14.5 million and $15.5 million for the fourth quarter of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2024
-0.9%
Avg return
Earnings day
-0.4%
Avg return
5 days after
-1.6%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+36.7%
Q3 2024
Best reaction
-39.0%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -6.7% | -13.3% | -29.2% | |
| Q4 2025 | -13.0% | -14.8% | +32.3% | |
| Q3 2025 | +0.8% | -3.4% | -8.5% | |
| Q1 2025 | -39.0% | -32.0% | -15.7% | |
| Q4 2024 | -7.2% | -8.4% | -28.8% | |
| Q3 2024 | +36.7% | +30.2% | +48.8% | |
| Q2 2024 | -17.5% | -14.4% | +3.3% | |
| Q1 2024 | -33.8% | -39.7% | -55.0% | |
| Q4 2023 | -1.4% | -6.1% | -19.6% | |
| Q3 2023 | -1.2% | +0.5% | +50.4% | |
| Q2 2023 | +6.2% | +5.7% | +2.3% | |
| Q1 2023 | +24.0% | +34.2% | +41.1% | |
| Q4 2022 | +3.1% | +5.9% | -24.2% | |
| Q3 2022 | +2.7% | +21.4% | +43.1% | |
| Q2 2022 | +22.1% | +24.6% | +4.6% | |
| Q1 2021 | -3.4% | -12.0% | -6.3% | |
| Q1 2022 | +12.6% | +28.5% | +14.0% | |
| Q4 2021 | +0.9% | +0.0% | -21.2% | |
| Q3 2021 | +4.8% | +4.1% | -36.5% | |
| Q2 2020 | -4.7% | -13.0% | -13.0% | |
| Q2 2021 | -5.6% | -7.5% | -15.8% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro